Sarcopenia is the progressive loss of skeletal muscle that is linked to aging. Though the condition affects many older adults’ functional abilities, it has not always garnered much public attention.
Sarcopenia is gaining even more recognition through the U.S. Food and Drug Administration’s call for comments at an upcoming public meeting on Patient-Focused Drug Development (PFDD) for Sarcopenia on April 6, 2017, from 1 to 5 p.m. EST.
If you or someone you know has sarcopenia, the FDA wants to hear from you!
You can participate in the meeting in person or virtually through a live webcast.
If you’re interested in attending in person, the meeting will be held at the Tommy Douglas Conference Center in Silver Spring, Md. Registration for the meeting ends on March 27, 2017. You can find registration details here.
If you’re unable to join the meeting and cannot watch online, you can also offer comments through the public docket. Comments can be sent electronically or through the U.S. mail. All submissions must include the Docket No. FDA-2016-N-4198 for “Public Meeting on Patient-Focused Drug Development for Sarcopenia; Request for Comments.” The docket closes on June 6, 2017. For more, please go here.